N°XXXX Rapid detection of extended-spectrum BETA-lactamase producing Enterobacteriaceae from urine using the ESBL NDP test Patrice Nordmann, Laurent Poirel,

Slides:



Advertisements
Similar presentations
Resistant Gram-negative Infections 21 st March 2013 Acute Medicine Study Day Dr Sarah Glover Consultant in Medical Microbiology and Infectious Diseases.
Advertisements

Prevalence of ESBL and MBL antibiotic resistance genes in Klebsiella pneumoniae in Pretoria Academic Hospital Maningi NE, Ehlers MM, Hoosen AA, Makgothlo.
Emerging Antimicrobial Resistance in Texas The new ESBLs.
2009 CLSI M100-S19 Update Nebraska Public Health Laboratory.
Methods for detection β-lactamases Sarah Alharbi.
Welcome to the CDS Workshop Jeanette Pham Syd Bell Hobart 2011.
Plasmid mediated Metallo-Beta- Lactamase (MBL) Plasmid mediated Hydrolyses all beta-lactam (except aztreonam) Inhibited by EDTA Binds zinc (Zn 2+ ) Pseudomonas.
Resistance to  -lactam antibiotics within the Enterobacteriaceae Paul D. Fey, Ph. D. University of Nebraska Medical Center.
ANTIMICROBIAL RESISTANCE
1 Extended spectrum B-lactamase producing E.coli in the community and in hospital Dr Graham Harvey Consultant Microbiologist Director of Infection Prevention.
Detection of  -lactamase- mediated resistance David Livermore Health Protection Agency, Colindale, London.
Using Nursing Home Antibiograms To Improve Antibiotic Prescribing and Delivery Training Slides for Prescribing Clinicians Comprehensive Antibiogram Toolkit.
Aims of study This surveillance study was performed to determine the in vitro activity of ciprofloxacin against clinical isolates of Escherichia coli and.
Antimicrobial Resistance patterns among nosocomial gram negative bacilli by E-test and disc diffusion methods in Sina and Imam Hospital.
Interpretation/Evaluation of Laboratory Data CLS 552 Human Microbiology & Immunology Laboratory Note: View this PowerPoint as a ‘Full Screen Slide Show’.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Antimicrobial resistance surveillance in Ireland Results of invasive Klebsiella pneumoniae infection (blood/CSF) surveillance, 2009 **** Data as of 01/12/2010.
Multi-Resistant Gram Negative Microorganisms St Elisabeth Hospital Curacao.
(Ambler class A, Bush group 2) Inhibited by CA
4/28/2017 AST.
Using Nursing Home Antibiograms To Improve Antibiotic Prescribing and Delivery Training Slides for Nursing Home Nurses Comprehensive Antibiogram Toolkit.
MRSA, ESBLs and Carbapenem Resistance
C-158 Genetic and Biochemical Characterisation of OXA-405, a New Extended Spectrum Class D -Lactamase from Serratia marcescens L. Dortet1,2, S. Oueslati1,
Tapasyapreeti Mukhopadhyay, Vrushali Patwardhan, Sarman Singh
Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae
Antibiotic-resistant Bacteria
Characterization of B-lactam resistance mechanisms among UTI isolates collected from women attending primary care across Europe- RGNOSIS P th ECCMID.
Nitroxoline does not result in microbiological eradication in geriatric patients with lower urinary tract infection: a prospective cohort study C. Forstner1,2*,,
Current Status of Antimicrobial Resistance
Etiology of bacteremia in children under 5 years in Southern Mali
Amela Dedeić-Ljubović
Serotypes, genotypes and antimicrobial resistance patterns of human diarrhoeagenic Escherichia coli isolates circulating in southeastern China  Y. Chen,
Epidemiological and bacteriological findings
Afaq R. Afridi, Tanveer Ahmad, Arshad Hussain and Abdul Samad.
EARS-Net data on Antimicrobial Resistance in Ireland, Q
Carbapenems A Novel Drug Class :Evaluation Of Comparative Efficacy Against In Patients & Out Patients Resistant Isolates Amna Islam, Fiza Naz, Maham Razi,
Alphabet Soup: MRSA – ESBL - CRE
Are Vitek2 system and E-test relevant and reliable for determining susceptibility to temocillin? Visée C.1, Frippiat F1, Descy J.2, Meex C.2, Melin P.2,
International Journal of Infectious Diseases
The Role of the Microbiology Laboratory in AMS programs
Average susceptibility
Cell wall inhibitor Cephalosporins Dr. Naza M. Ali Lec D
F.M. MacKenzie, C.A. Miller, I.M. Gould 
Environmental stress exacerbate the emergence of Multidrug
Antibiotic Susceptibility patterns of culture-positive urine isolates in children under 14 years. Paul Ombuya Laboratory technologist At GCH October 2013.
Clinico-Pathological Conference (CPC) Meet
Antibiotics sensitivity of microorganism causing nosocomial infections
Prevalence of CTX-M-14 type in Welsh Hospitals
Dr David Garner Consultant Microbiologist
Table 1: Resistance profile
Antimicrobial Resistance: from Global to Local
Extended-spectrum beta-lactamases(ESBL)
Cephalosporin and Cell Wall Synthesis Inhibitors
C th Interscience Conference on Antimicrobial Agents and Chemotherapy October 25-28, Washington, DC Examining Temocillin Activity in Combination.
L. Poirel, P. Nordmann  Clinical Microbiology and Infection 
Impact of changes in CLSI and EUCAST breakpoints for susceptibility in bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia.
Rapid detection of enterobacteriaceae producing extended spectrum beta-lactamases directly from positive blood cultures by matrix-assisted laser desorption.
Evaluation of a diagnostic flow chart for detection and confirmation of extended spectrum β-lactamases (ESBL) in Enterobacteriaceae  S. Polsfuss, G.V.
Phenotypic detection of extended-spectrum β-lactamase production in Enterobacteriaceae: review and bench guide  L. Drieux, F. Brossier, W. Sougakoff,
Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin- clavulanate and piperacillin-tazobactam with extended-spectrum.
TRAINING PRESENTATION
C. Varela, A. Oliver, T.M. Coque, F. Baquero, R. Canton 
β- Lactamase Inhibitor
Mechanisms of Resistance and Clinical Relevance of Resistance to β-Lactams, Glycopeptides, and Fluoroquinolones  Louis B. Rice, MD  Mayo Clinic Proceedings 
I. Faria-Ramos, M. J. Espinar, R. Rocha, J. Santos-Antunes, A. G
Jacques Sirot  Clinical Microbiology and Infection 
Mechanisms of reduced susceptibility to amoxycillin-clavulanic acid in Escherichia coli strains from the health region of Tortosa (Catalonia, Spain) 
Predominance of SHV-5 β-lactamase in enteric bacteria causing community-acquired urinary tract infections in Bosnia and Herzegovina  S. Uzunovic-Kamberovic,
PRACTICAL GUIDE THE PROCESS OF TESTING
Serotypes, genotypes and antimicrobial resistance patterns of human diarrhoeagenic Escherichia coli isolates circulating in southeastern China  Y. Chen,
Presentation transcript:

N°XXXX Rapid detection of extended-spectrum BETA-lactamase producing Enterobacteriaceae from urine using the ESBL NDP test Patrice Nordmann, Laurent Poirel, and Laurent Dortet  University of Fribourg, Fribourg, Switzerland (L. Poirel, P. Nordmann) Hopital Fribourgeois-hôpital Cantonal, Fribourg, Switzerland (P. Nordmann) INSERM U914, K.-Bicêtre, France (L. Dortet, L. Poirel, P. Nordmann) INTRODUCTION METHODS RESULTS Multidrug resistance is now emerging worldwide at an alarming rate among Gram negatives, causing both community-acquired and nosocomial infections. One of the most important emerging resistance traits corresponds to resistance to broad-spectrum ß-lactams in Enterobacteriaceae, which is mainly associated to production of clavulanic acid inhibited extended-spectrum ß-lactamases (ESBLs). A variety of ESBLs have been reported in Enterobacteriaceae, being mostly of the CTX-M-, TEM- and SHV-types. ESBL producers are mostly Escherichia coli and Klebsiella pneumoniae, being the main source of community- and hospital-acquired infections. In addition, those bacteria are responsible for divers types of infection among which urinary tract infections are predominant. This detection is necessary in order to screen patients, and subsequently improve hospital infection control practices, to curb inappropriate antibiotic use, and therefore to prolong the efficacy of the currently available antibiotics. Recently, the ESBL NP test has been developed for a rapid identification of ESBL-producing Enterobacteriaceae. This technique, based on the detection of hydrolysis of the β-lactam ring of a 3rd generation cephalosporin, cefotaxime, is rapid, sensitive and specific. From June to September 2012, the ESBL NDP test was performed on 450 urine samples recovered from patients hospitalized in a tertiary care center. Urine specimens with more than 104 leucocytes/ml and positive for Gram-negative bacilli after Gram staining were included in the study. Results of the ESBL NDP test were compared to those of the antibiogram and the double disk diffusion method. Subsequently, all ESBL producers were characterized phenotypically (MIC determination) and at their molecular level. ESBL NDP test on urine samples (n=450) Figure 1. Design and results of the study All ESBL-E were resistant to cefotaxime (the substrate used in the ESBL NDP test) except a single E. coli isolate producing TEM-24 (Table 1). These isolates were also resistant to other non-β-lactam antibiotics used for treating UTIs such as gentamicin (64.7%), co-trimoxazole (83.3%), fosfomycin (27.5%), ciprofloxacin (83.3%), amoxicillin + clavulanate (29.4%), piperacillin + tazobactam (13.7%), cefoxitin (15.7%), nitrofurantoin (9.8%), and remained susceptible to all carbapenems (imipenem, ertapenem, meropenem) and to temocillin. NI _ + n = 49 n = 6 n = 395 UriSelect™ 4 UriSelect™ 4 UriSelect™ 4 ESBL NDP test on grown colonies ESBL NDP test on grown colonies ESBL NDP test on grown colonies ESBL NP test Principle Protocol Interpretation after 20 min _ _ _ Acid production + + + n = 48 n = 1 n = 2 n = 0 n = 4 n = 395 H2N R COOH R’ O HO S pH Non-ESBL Non-ESBL Non-ESBL Non-ESBL Non-ESBL Non-ESBL ESBL ESBL ESBL ESBL ESBL ESBL 3rd generation cephalosporin n = 48 n = 0 n = 0 n = 1 n = 2 n = 0 n = 0 n = 4 n = 0 n = 0 n = 1 n = 394 N O R S COOH R’ Colorimetric detection OXA-1 producing E. coli TEM-24-producing E. coli ESBL Table 1. Characterization of the ESBL producers N O R S COOH R’ Species CFU / ml β-Lactamase content ESBL NDP test on urine ESBL NDP test on colonies MICs (μg/ml) CTX CTX + TZB CAZ CAZ + TZB FEP FEP + TZB E. coli 1.2.106 CTX-M-1 + - 8 0.125 2 0.016 3 0.023 2.106 24 0.032 1.5 3.8.107 32 0.25 12 2.8.107 CTX-M-1 + TEM-1 4 48 0.094 16 1.1.107 0.19 6 0.064 CTX-M-3 + SHV-12 0.047 9.4.107 CTX-M-14 1 2.8.108 6.107 CTX-M-14 + TEM-1 0.75 1.3.106 CTX-M-15 >256 3.3.107 9.8.107 192 5.2.108 4.1.107 2.3.108 96 6.5.107 5.3.107 9.4.106 1.6.107 1.2.108 64 1.8.107 128 9.5.106 CTX-M-15 + TEM-1 2.1.108 6.3.107 6.108 4.107 6.2.108 0.38 3.4.107 NI 9.108 CTX-M-27 + TEM-1 8.9.106 TEM-24 K. pneumoniae 3.1.106 1.1.108 CTX-M-15 + SHV-1 CTX-M-15 + SHV-1 + TEM-1 4.3.108 0.5 3.7.107 2.7.108 1.3.108 4.3.107 3.9.108 3.1.107 C. freundii CTX-M-3 C. koseri 2.1.107 E. cloacae 5.1.107 5.107 1.5.108 1.4.108 SHV-12 + TEM-1 +/- 0.119 (cefotaxime) + tazobactam Stable pH A B C 100 μl B-PER II lysis buffer A B C 0.5 ml H2O A B C 1.5 ml Urine Remove the supernatant Remove the supernatant Characteristics of the ESBL NDP test directly performed on clinical urine samples Sensitivity 98.0 % Specificity 99.8 % Positive predictive value Negative predictive value Centrifugation 2 min at 12 000 g Centrifugation 2 min at 12 000 g A B C 100 μl PR solution + cefotaxime (at 6 mg/ml) A B C 100 μl PR solution 10 μl Tazobactam (at 40 mg/ml) CONCLUSIONS PURPOSE Using the ESBL NDP test directly on urine led to detect all ESBL producers except two that were susceptible to cefotaxime and two that were found in not significative concentration in the urine sample. Only 1.3% of non interpretable results were obtained. A B C Evaluate the ability of the ESBL NP test to detect ESBL producers among Enterobacteriaceae directly from urine samples. Overexpressed cephalosporinase+/- ESBL Not interpretable ESBL No BLSE A B C A B C A B C A B C